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The poliovirus receptor: a hook, or an unzipper?
Vincent R Racaniello
The cell receptor for poliovirus may be more than a
simple ‘snare’ that attaches virus to cells. Recent
results indicate that receptor binding may cause
conformational changes in the virus that lead to
uncoating of the viral RNA.
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All viruses must bind to a cell surface receptor to initiate
infection. Some viruses, such as influenza virus, appear to
use the cell receptor as a tether to hold the virus in place
while the hemagglutinin mediates membrane fusion in
response to low pH [1]. Many enveloped viruses undergo
fusion with cell membranes at neutral pH, and the inter-
action with the cell receptor may trigger conformational
changes in viral glycoproteins that convert them to fuso-
genic forms [2]. Non-enveloped viruses have the particu-
larly difficult problem of how to transport the viral nucleic
acid through a protein shell and across the cell mem-
brane. Adenovirus is brought into the endocytic pathway
by its cell receptor, but the receptor does not appear to
participate in the stepwise disassembly of the particle
that subsequently occurs [3]. It has been known for many
years that the interaction of poliovirus with susceptible
cells leads to the production of a conformationally altered
particle [4] that is believed to be an intermediate in cell
entry [5]. The determination of the three-dimensional
structure of the viral capsid [6] and identification of the
cell receptor for poliovirus [7] have lead to a better struc-
tural understanding of the virus–receptor interactions that
lead to cell entry.
The cell receptor for poliovirus
The capsid of each of the three serotypes of poliovirus con-
sists of sixty copies each of four viral proteins, VP1, VP2,
VP3 and VP4. The poliovirus receptor (PVR), which is used
by all three viral serotypes to initiate infection of cells, is a
novel member of the immunoglobulin superfamily [7]. The
PVR polypeptide contains an N-terminal signal sequence,
three extracellular immunoglobulin (Ig)-like domains, a
transmembrane domain, and a cytoplasmic tail. Alternative
splicing results in two mRNAs encoding polypeptides of
392 and 417 amino acids: the two forms differ in the lengths
of their cytoplasmic domains. Both forms of PVR function
as receptors for poliovirus. The predicted molecular sizes 
of the two polypeptides are 43 and 45 kDa, respectively,
although post-translational modification in HeLa cells pro-
duces a predominant species of 80 kDa [8].
Two human genes related to PVR, PRR1 and PRR2,
have been identified, although it is not known if the
encoded polypeptides function as poliovirus receptors
[9,10]. A mouse homolog, MPH, does not bind poliovirus
[11], including those that are adapted to grow in mice
(Y Dong and VR, unpublished data). The cellular func-
tions of PVR, PRR1, PRR2 and MPH are unknown
although, like many members of the Ig superfamily, they
may play a role in cell adhesion and recognition. The
cytoplasmic domain of one isoform of PVR is phosphory-
lated at serine, possibly by calcium-calmodulin kinase II
[12], and several protein kinases bind to and phosphory-
late the cytoplasmic domain of MPH (Y Dong and VR,
unpublished data). Identification of these protein kinases
should provide clues about the normal role of PVR and
MPH in the cell. 
The role of PVR in uncoating of viral RNA
Shortly after poliovirus binds to cell surface PVR, it
releases its RNA genome into the cytoplasm. PVR is
likely to play a role in the uncoating step, as suggested by
its ability to induce dramatic structural changes in the
virus particle. When poliovirus is bound to cells at 37°C, a
large proportion of the virus is eluted as a conformationally
altered form known as the A particle [4]. These particles
contain infectious RNA, but they differ from native virus
in their sedimentation coefficient (135S compared with
160S for native virions), their increased sensitivity to
detergent and proteinases, and the absence of VP4 [5].
The N terminus of VP1, normally on the interior of the
virion, has been translocated to the surface, making the
capsid hydrophobic. Conversion of poliovirus to 135S par-
ticles can also be accomplished in solution by incubation
with detergent extracts of insect cells expressing PVR
[13], or with soluble PVR released into the culture
medium from expressing cells [14]. It is likely that PVR is
sufficient for 135S particle formation, although this possi-
bility has not yet been tested with the purified protein.
The A particle has been proposed to be an essential inter-
mediate in the entry of poliovirus into cells ([5]; see the
article by James Hogle in this issue of Structure). The
N terminus of VP1 may form an amphipathic helix that
inserts into the cell membrane, producing a pore through
which the viral RNA may leave the capsid. To determine
the role of 135S particle formation in poliovirus replication,
we took advantage of the observation that A particles are
not formed at temperatures below 33°C [15], and deter-
mined whether poliovirus could replicate at 25°C (A Dove
and VR, unpublished data). Our findings indicate that the
Mahoney strain of type 1 poliovirus, P1/Mahoney, is unable
to grow at 25°C, but cold-adapted (CA) mutants are readily
selected at this temperature. CA mutants replicate effi-
ciently at 25°C without forming 135S particles (they do
form 135S particles at 37°C). The CA phenotype does not
map to the capsid-coding region of the viral genome, but
rather to a central region encoding non-structural proteins.
This suggests that the block to replication in WT
P1/Mahoney occurs after the stage of cell entry, for
example in RNA replication, proteolytic processing, or even
assembly. In support of this hypothesis, when the entry
steps are by-passed by transfection of viral RNA into cells,
CA viral RNA replicates at 25°C, but WT RNA does not.
These results suggest that formation of 135S particles is
not required for poliovirus replication. The altered particle
might be a dead end and perhaps a less drastic PVR-
induced conformational change might the true inter-
mediate in RNA uncoating. The ability to study a
productive poliovirus infection at 25°C, in the absence of
135S particle formation, should enable the identification
of such structural changes. We are left with the intriguing
question of why poliovirus produces so many nonfunc-
tional 135S particles; perhaps it is the price that must be
paid for the ability to undergo receptor-mediated struc-
tural changes. Formation of 135S particles has been largely
studied in cultured cells; in vivo, where the accessibility
and/or level of cell receptors might be limited, it may be
that fewer A particles are generated.
PVR sequences that mediate virus binding
To fully understand how the poliovirus–PVR interaction
initiates cell entry, a detailed picture of how the virus and
receptor combine is required. Ultimately, resolution of a
virus–receptor complex will be needed, but the results of
genetic analyses have already provided some insight into
the interaction. The binding site for poliovirus appears to
be contained within domain 1 (Fig. 1), which can bind
poliovirus when expressed on the cell surface either alone
or linked to other domains from CD4, ICAM-1 or MPH
(reviewed in [16]). Virus does not bind as well to domain
1 as it does to native PVR, suggesting that domains 2 and
3 contribute to the interaction either directly or by influ-
encing the structure of domain 1. Several laboratories
have carried out mutational analyses on PVR domain 1 to
identify the putative contact point, and the results show
that three main sites are important for poliovirus binding
(Fig. 1): the C–C′ loop through the C′′ strand; the border
of the D strand and the DE loop; and the G strand. A
mutation at the beginning of the F strand also reduces
virus binding, probably by altering domain structure.
Mutagenesis of other loops and strands has not revealed
other regions that are important for binding.
These studies indicate that the C′–C′′ ridge is likely to be
the main part of PVR that contacts poliovirus. The homolo-
gous part of CD4 plays a major role in the interaction with
human immunodeficiency virus type 1 (reviewed in [17]).
The DE loop of domain 1 may also contact poliovirus, but
the G strand is more distant and not likely to be a compo-
nent of the binding site. Consistent with this hypothesis is
the observation that substitution of the region comprising
PVR residues 70–100, which contains the C′–C′′ ridge (Fig.
1), into the corresponding region of MPH produces a
chimeric receptor that can be recognized by type 1 but not
types 2 and 3 poliovirus (Y Lin and VR, unpublished data).
This result suggests that the poliovirus-binding site on
PVR is contained within this 30 amino acid segment,
although contribution of conserved MPH residues to
poliovirus binding cannot be excluded. Apparently, the
three serotypes of poliovirus contact PVR slightly differ-
ently, a conclusion also drawn from studies of the G-strand
mutation (Fig. 1), which abrogates binding of types 1 and 2
but not type 3 poliovirus [18]. 
Viral capsid sequences that mediate PVR interaction
When the three-dimensional structures of rhinovirus and
poliovirus were solved, a 1.2 nm deep, 1.5 nm wide channel
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Figure 1
Structural model of PVR domain 1 [25]. The locations of mutations that
influence poliovirus binding, shown in white, are given as amino acid
numbers, beginning with the first methionine of PVR [7], or as letters
for mutations: d (Gln → Phe at amino acid 82), g (insertion of
Val–Asp–Phe at amino acid 56), and i (change of Leu–Glu at amino
acid 99 to Pro–Glu–Thr–Asn). b strands are labeled with uppercase
letters.
was noted surrounding the prominent peak at the fivefold
axis of symmetry of the particle [6,19]. This channel was
called the canyon, and was proposed to be the receptor-
binding site for rhinovirus 14 [19]. A model of the inter-
action of human rhinovirus 16 with its soluble receptor,
ICAM-1, indicates that ICAM-1 does bind in the canyon
[20]. Evidence that the canyon is the receptor-binding
site in poliovirus comes from the study of two types of
viral mutants: soluble receptor resistant (srr) mutants, and
viruses adapted to utilize mutant PVRs. Detergent-
solubilized PVR expressed in insect cells converts
poliovirus to 135S particles, effectively neutralizing its
infectivity [13]. Poliovirus mutants resistant to neutraliza-
tion with soluble PVR have been selected; these mutants
possess a range of binding defects to PVR [21,22]. Each
srr mutant contains a single mutation, located either on
the surface or the interior of the capsid. The surface
mutations (white spheres in Fig. 2) are located in the
canyon, and may be part of the contact site for PVR.
Mutation at any one of eight surface residues decreases
the binding affinity of poliovirus for PVR, indicating that
multiple points in the virus–receptor interface contribute
to binding. Mutations at internal capsid residues also
reduce binding affinity. These residues are not likely to
contact the receptor directly, but may affect the ability of
the virus to bind to PVR with high affinity by altering the
flexibility of the capsid. The proximity of several of the
internal mutations to a hydrocarbon-binding pocket that
appears to contain sphingosine [23] is consistent with this
hypothesis. This pocket is believed to regulate the ability
of the capsid to undergo receptor-mediated structural
transitions [23]. 
Additional information on capsid sequences that control
receptor interaction comes from the analysis of viral vari-
ants that are adapted to grow on cells expressing mutant
forms of PVR that do not bind WT poliovirus P1/Mahoney
[24]. PVR mutants d, g and i (Fig. 1) were constructed by
substituting residues of PVR with corresponding residues
from MPH. Because MPH is not a poliovirus receptor, this
analysis identifies regions of PVR important for poliovirus
binding [25]. Stable cell lines that express d, g or i mutants
were derived from the mouse fibroblast line L. These cell
lines cannot bind poliovirus, but viral variants were readily
isolated that can utilize the mutant PVRs to infect cells.
These adapted viruses can still utilize WT PVR to infect
cells, and therefore possess an expanded receptor recogni-
tion. Sequence analyses and site-directed mutagenesis
identified three different sites of mutations that are
responsible for the adapted virus phenotype (Fig. 2; muta-
tions shown as yellow spheres). Every adapted mutant con-
tained a change at VP1 position 95, from proline to serine
or threonine (P1095S/T; in this nomenclature, the first
letter is the amino acid found in the WT virus, the next
digit indicates the capsid protein VP1, VP2, VP3 or VP4,
the next three digits the amino-acid position and the last
letter the mutant amino acid). When either amino acid is
introduced into WT virus by site-directed mutagenesis,
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Figure 2
Ca trace of the poliovirus type 1 Mahoney
pentamer [6], tilted on the X axis. Each
protomer is shown in a different color, and the
fivefold axis of symmetry is labeled.
Sphingosine in the hydrocarbon-binding
pocket is shown as gray spheres, srr
mutations are shown as white spheres, and
adapting mutations are shown as yellow
spheres. In the two protomers at the forefront,
adapting mutation 1095 is near the fivefold
axis, 1160 is near the top of the sphingosine,
and 2142 is to the bottom and left of the
sphingosine.
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viruses are produced that can use all three mutant recep-
tors. Position 95 of VP1 is located in the BC loop at the
fivefold axis of symmetry, distant from the putative recep-
tor contact site defined by srr mutations (Fig. 2). Although
it is possible that this portion of the capsid also contacts
PVR, the lack of allele specificity of the P1095S/T adapt-
ing mutation suggests that this residue is not likely to
contact the mutated portions of PVR. This sequence might
instead modulate the flexibility of the capsid and its ability
to accommodate mutant receptors. Substitution of the
entire VP1 BC loop with the sequence from the mouse-
adapted Lansing strain of poliovirus type 2, P2/Lansing,
enables P1/Mahoney to recognize an unidentified receptor
in mice that cannot be used by the WT virus [26,27]. In
this case, the VP1 BC loop of P2/Lansing may directly
contact the mouse receptor, or it may impart to the capsid
the flexibility to recognize a new receptor.
A second adapting mutation, V1160I, is located at the
interface between protomers (the capsid subunit consist-
ing of one copy each of VP1, VP2, VP3 and VP4), near the
hydrophobic binding pocket of VP1. This mutation is not
allele specific, and might also act by influencing the flexi-
bility of the capsid. The V1160I mutation also allows
P1/Mahoney to recognize a receptor in mice, thereby
causing disease in that host. The mouse-adapted
P2/Lansing contains isoleucine at amino acid 1160; curi-
ously, it can utilize the g receptor but not the d and i
receptors. A third adapting mutation, H2142Y, is located
on the canyon wall near the receptor-binding site defined
by the srr mutations. This mutation is allele specific, and
will only correct the defect conferred by the d and g muta-
tions, which are adjacent in PVR (Fig. 1). The nature of
the amino acid at this location in the capsid may influence
the contact point with PVR. The Leon strain of type 3
poliovirus contains tyrosine at 2142 but can only bind the
d receptor. These studies emphasize the serotype-specific
differences in the interaction of poliovirus with PVR. 
Does PVR work alone?
A mAb called AF3, which is directed against HeLa cells
and blocks the binding of poliovirus to these cells in a
serotype-specific manner [28], recognizes a specific iso-
form of the lymphocyte homing receptor CD44H [29].
This cell surface molecule is not a receptor for poliovirus,
because expression of CD44H cDNA in PVR-negative
mouse L cells does not confer the ability to bind
poliovirus. Because the expression of the AF3 epitope is
restricted to certain tissues that are susceptible to
poliovirus infection, it was suggested that CD44 might be
a determinant of poliovirus tissue tropism [28]. However,
the results of growth curve analyses indicate that all three
poliovirus serotypes multiply normally in cells that
express PVR but not CD44, and the addition of CD44 by
stable transformation has no effect on virus multiplication.
Furthermore, the binding affinity constant for all three
poliovirus serotypes is identical in the presence or absence
of CD44. We conclude that CD44 is not required for
poliovirus replication in cell culture. CD44H and PVR
may be associated in the cell membrane, and AF3 may
block poliovirus binding by its proximity to the virus-
binding site on PVR.
Summary
These studies paint a hypothetical picture of the inter-
action of poliovirus with PVR, and how this union might
initiate the uncoating steps. Contact between the virus and
receptor occurs between capsid residues in the canyon and
residues of the C′–C′′ ridge on domain 1 of PVR. High
affinity binding is probably dependent both on the nature
of the contact residues in the virus and the receptor, and on
capsid residues at the protomer interface and in the interior
that give flexibility to the capsid and allow it to conform to
the receptor. Because the contact points in the canyon are
located at the protomer interface, above the hydrocarbon-
binding pocket, the interaction with PVR probably begins
to destabilize the interface and weaken the affinity of
sphingosine for the pocket. As the cell membrane wraps
around the particle, additional PVR molecules bind to the
capsid, perhaps releasing sphingosine and leading to
complete destabilization of the capsid. The RNA might
then emerge from an opening at the protomer interface.
Crystallographic resolution of the virus–receptor complex
will be required to demonstrate precisely how the virus and
receptor interact. Whether or not PVR, either in soluble
form or associated with membranes, is sufficient to drive
RNA uncoating can also be determined experimentally.
Finally, the location in the cell at which the uncoating
event occurs must be identified. These experiments will
provide clues about how cell receptors participate in the
uncoating of an icosahedral virus.
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